Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei Min Liu

Showing results (161-170 of 163) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 163 results.
Blood|September 8, 2012
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y Xu-Monette, Lin Wu, Carlo Visco, et al.
Blood|January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.
Haematologica|August 30, 2012
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Alexander Tzankov, Zijun Y Xu-Monette, et al.
Pageof 17

Showing results (161-170 of 163) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 163 results.
Blood|September 8, 2012
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y Xu-Monette, Lin Wu, Carlo Visco, et al.
Blood|January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.
Haematologica|August 30, 2012
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Alexander Tzankov, Zijun Y Xu-Monette, et al.
Pageof 17